A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study.
Matsumoto K, Takayama N, Aisa Y, Ueno H, Hagihara M, Watanabe K, Nakaya A, Chen K, Shimizu T, Tsukada Y, Yamada Y, Nakazato T, Ishida A, Miyakawa Y, Yokoyama K, Nakajima H, Masuda Y, Yano T, Okamoto S; Keio BRB Study Group.
Matsumoto K, et al. Among authors: takayama n.
Int J Hematol. 2015 Jun;101(6):554-62. doi: 10.1007/s12185-015-1767-3. Epub 2015 Mar 19.
Int J Hematol. 2015.
PMID: 25783753
Clinical Trial.